Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload

This publication has 36 references indexed in Scilit:

• Effects of the sodium‐glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan
  Nephrology, 2018
• Biochemical Determinants of Changes in Plasma Volume After Decongestion Therapy for Worsening Heart Failure
  Journal of Cardiac Failure, 2018
• Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
  Diabetes, Obesity and Metabolism, 2017
• Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus
  Clinical Therapeutics, 2016
• Hypochloremia and Diuretic Resistance in Heart Failure
  Circulation: Heart Failure, 2016
• Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
  Diabetes & Vascular Disease Research, 2015
• Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
  Diabetes Care, 2015
• Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus
  Diabetes, Obesity and Metabolism, 2014
• Potential Effects of Aggressive Decongestion During the Treatment of Decompensated Heart Failure on Renal Function and Survival
  Circulation, 2010
• The Haemodynamic Effects of Correction of Anaemia in Haemodialysis Patients Using Recombinant Human Erythropoietin
  Nephrology Dialysis Transplantation, 1990